Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pascal Machiels

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
European Urology Oncology|October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to TherapyKarim Fizazi, Johann S de Bono, A Douglas Laird, et al.
Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Journal of the National Cancer Institute|September 20, 2017
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on SurvivalBernhard Mlecnik, Marc Van den Eynde, Gabriela Bindea, et al.
Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Urologic Oncology|February 7, 2016
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use programCharles Van Praet, Sylvie Rottey, Fransien Van Hende, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
European Urology Oncology|October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to TherapyKarim Fizazi, Johann S de Bono, A Douglas Laird, et al.
Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Journal of the National Cancer Institute|September 20, 2017
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on SurvivalBernhard Mlecnik, Marc Van den Eynde, Gabriela Bindea, et al.
Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Urologic Oncology|February 7, 2016
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use programCharles Van Praet, Sylvie Rottey, Fransien Van Hende, et al.
Pageof 17